BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
March 07 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, today
announced that it will report its fourth quarter and full year 2018
financial and operating results on Thursday, March 14th, 2019,
following the close of the U.S. financial markets. BioTime
management will also host a conference call and webcast on
Thursday, March 14th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m.
Pacific Time to discuss its fourth quarter and full year 2018
financial results and to provide a business update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and should request the “BioTime Inc.
Call”. A live webcast of the conference call will be available
online in the Investors section of BioTime’s website. A replay of
the webcast will be available on BioTime’s website for 30 days and
a telephone replay will be available through March 21st, 2019,
by dialing (855) 859-2056 from the U.S. and Canada and (404)
537-3406 from elsewhere outside the U.S. and entering conference ID
number 1091719.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please visit
www.biotimeinc.com. To receive ongoing BioTime corporate
communications, please click on the following link to join the
Company’s email alert list: http://news.biotime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190307005024/en/
BioTime Inc. IRIoana C. Hone(ir@biotimeinc.com)(510)
871-4188
Solebury Trout IRGitanjali Jain
Ogawa(Gogawa@troutgroup.com)(646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024